Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > how can an NR become not an NR?

<< Previous

Bullboard Posts

Next >>

Comment by DJDawgon Sep 05, 2022 9:29am

208 Views

Post# 34941965

RE:RE:how can an NR become not an NR?

What I mean is that in the previous release from 3 months ago, there were 14 NR at 270 days. That means that 14 patients were assessed and given that designation. I get that they could respond and become a PR or CR at the next timepoint or 360. But this is them going back and revising the 270 day designation on two patients so that there are only 12 NR in the newest report (vs 14 NR at 270).

It's not the same thing as the second treatment working and converting a patient. This is revising a previous categorization.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages